Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland 20892


Purpose:

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining melanoma vaccine with interleukin-2 is more effective than vaccine therapy alone in treating metastatic melanoma. PURPOSE: Phase II trial to compare the effectiveness of melanoma vaccine and interleukin-2 with that of melanoma vaccine alone in treating patients who have metastatic melanoma that has not responded to previous treatment.


Study summary:

OBJECTIVES: - Compare the clinical response in patients with metastatic melanoma treated with immunization with recombinant fowlpox vaccine administered either intravenously or intramuscularly, with or without interleukin-2 (IL-2). - Compare the immune response in patients before and after treatment with these regimens. - Compare the toxicity profile of these regimens in these patients. OUTLINE: This is a partially randomized study. Patients are randomized to 1 of 3 treatment cohorts. - Cohort 1: Patients receive recombinant fowlpox virus encoding gp100 peptide (fowlpox vaccine) IV once every 4 weeks for up to 4 doses. (Closed to accrual as of 6/21/02.) - Cohort 2: Patients receive fowlpox vaccine intramuscularly (IM) once every 4 weeks for up to 4 doses. (Closed to accrual as of 6/21/04.) - Cohort 3 (for patients in need of immediate interleukin-2 [IL-2] and those with disease progression after treatment in cohorts 1 or 2): Patients receive fowlpox vaccine either IV or IM* once every 4 weeks for 4 doses and IL-2 IV every 8 hours for a maximum of 12 doses beginning 24 hours after fowlpox vaccine. NOTE: *The IM route of administration was selected as the preferred route of administration from cohorts 1 and 2 - Expanded cohort 2 (open to accrual 7/19/02): Patients receive fowlpox vaccine IM once every 4 weeks for up to 4 doses. Upon disease progression, patients receive fowlpox vaccine as above and IL-2 IV every 8 hours for a maximum of 12 doses beginning 24 hours after fowlpox vaccine. (Closed to accrual 12/4/03.) In all cohorts, 3-4 weeks after the last injection, patients achieving a complete remission may receive a maximum of an additional 2 courses of therapy. Patients with responding disease may receive repeat vaccinations for up to 8 courses. Patients with no response or progressive disease in cohorts not receiving IL-2 may be treated with fowlpox vaccine and IL-2 as in cohort 3. Patients who are randomized to receive IL-2 may not receive additional IL-2 therapy. PROJECTED ACCRUAL: A maximum of 84 patients (24 in cohorts 1 and 2, 19-33 in cohort 3, and 27 in expanded cohort 2) will be accrued for this study within 1 year.


Criteria:

DISEASE CHARACTERISTICS: - Histologically proven metastatic melanoma that has failed standard treatment - Measurable disease - HLA-A-201 positive PATIENT CHARACTERISTICS: Age: - 16 and over Performance status: - ECOG 0-2 Life expectancy: - More than 3 months Hematopoietic: - WBC ≥ 3,000/mm^3 - Platelet count ≥ 90,000/mm^3 - No coagulation disorders Hepatic: - Bilirubin ≤ 1.6 mg/dL (less than 3.0 mg/dL for patients with Gilbert's syndrome) - AST/ALT < 2 times normal - Hepatitis B surface antigen negative Renal: - Creatinine ≤ 2.0 mg/dL Cardiovascular: - No major cardiovascular disease - No cardiac ischemia by a stress thallium test or other comparable test* - No myocardial infarction* - No cardiac arrhythmias* NOTE: *In order to be eligible to receive interleukin-2 (IL-2) Pulmonary: - No major respiratory disease - No obstructive or restrictive pulmonary disease* NOTE: *In order to be eligible to receive IL-2 Immunologic: - No autoimmune disease - No known immunodeficiency disease - No primary or secondary immunodeficiency - No allergy to eggs - No active systemic infections - HIV negative Other: - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception - No other active major medical illness* NOTE: *In order to be eligible to receive IL-2 PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior gp100 vaccination Chemotherapy: - Not specified Endocrine therapy: - No concurrent steroids Radiotherapy: - Not specified Surgery: - Prior surgery for the malignancy allowed Other: - At least 3 weeks since other prior therapy for the malignancy


NCT ID:

NCT00019669


Primary Contact:

Study Chair
Steven A. Rosenberg, MD, PhD
NCI - Surgery Branch


Backup Contact:

N/A


Location Contact:

Bethesda, Maryland 20892
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.